CHS-1420: Ph I CHS-1420-03 data

The double-blind Phase I CHS-1420-03 trial in healthy volunteers showed that a single 40 mg dose of subcutaneous CHS-1420 met the primary endpoint of pharmacokinetic bioequivalence to Humira adalimuma...